saccharomyces boulardii and Reduced C-Reactive Protein Levels

• Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial.

  • 2021-08
  • RCT · n = 151
  • EBioMedicine 70
  • • Ayodeji Awoyemi
    • Cristiane Mayerhofer
    • Alex S Felix
    • Johannes R Hov
    • Samuel D Moscavitch
    • Knut Tore Lappegård
    • Anders Hovland
    • Sigrun Halvorsen
    • Bente Halvorsen
    • Ida Gregersen
    • Asbjørn Svardal
    • Rolf K Berge
    • Simen H Hansen
    • Alexandra Götz
    • Kristian Holm
    • Pål Aukrust
    • Sissel Åkra
    • Ingebjørg Seljeflot
    • Svein Solheim
    • Andrea Lorenzo
    • Lars Gullestad
    • Marius Trøseid
    • Kaspar Broch

  • PubMed: 34329947
  • DOI: 10.1016/j.ebiom.2021.103511

  4 Insights on

  • Reduced C-Reactive Protein Levels

  • High evidence
  • Large Human Trial
  • Clinical

  We observed no significant between-group differences in changes in ... C-reactive protein.

  Effect

  Neutral

  Effect size

  Small

  Significant

  No

• Effect of Saccharomyces boulardii on Liver Diseases: A Systematic Review.

  • 2024-08-15
  • Review
  • Microorganisms 12(8)
  • • Roman Maslennikov
    • Nona Benuni
    • Anna Levshina
    • Farida Adzhieva
    • Tatyana Demina
    • Alina Kucher
    • Ekaterina Pervushova
    • Evgeniya Yuryeva
    • Elena Poluektova
    • Oxana Zolnikova
    • Evgenii Kozlov
    • Alexey Sigidaev
    • Vladimir Ivashkin

  • PubMed: 39203520
  • DOI: 10.3390/microorganisms12081678

  2 Insights on

  • Reduced C-Reactive Protein Levels

  • Low evidence

  reduced the CRP levels in decompensated cirrhosis.

  Effect

  Beneficial

  Effect size

  Small

  Significant

  Yes